Research ExplorerPublicationsHigh nuclear karyopherin α 2 expression is a strong and inde...

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy

Standard

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. / Grupp, Katharina; Habermann, Mareike; Sirma, Hüseyin; Simon, Ronald; Steurer, Stefan; Hube-Magg, Claudia; Prien, Kristina; Burkhardt, Lia; Jedrzejewska, Karolina; Salomon, Georg; Heinzer, Hans; Wilczak, Waldemar; Kluth, Martina; Izbicki, Jakob R; Sauter, Guido; Minner, Sarah; Schlomm, Thorsten; Tsourlakis, Maria Christina.

In: MODERN PATHOL, Vol. 27, No. 1, 01.01.2014, p. 96-106.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Grupp, K, Habermann, M, Sirma, H, Simon, R, Steurer, S, Hube-Magg, C, Prien, K, Burkhardt, L, Jedrzejewska, K, Salomon, G, Heinzer, H, Wilczak, W, Kluth, M, Izbicki, JR, Sauter, G, Minner, S, Schlomm, T & Tsourlakis, MC 2014, 'High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy', MODERN PATHOL, vol. 27, no. 1, pp. 96-106. https://doi.org/10.1038/modpathol.2013.127

APA

Grupp, K., Habermann, M., Sirma, H., Simon, R., Steurer, S., Hube-Magg, C., Prien, K., Burkhardt, L., Jedrzejewska, K., Salomon, G., Heinzer, H., Wilczak, W., Kluth, M., Izbicki, J. R., Sauter, G., Minner, S., Schlomm, T., & Tsourlakis, M. C. (2014). High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. MODERN PATHOL, 27(1), 96-106. https://doi.org/10.1038/modpathol.2013.127

Vancouver

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C et al. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. MODERN PATHOL. 2014 Jan 1;27(1):96-106. https://doi.org/10.1038/modpathol.2013.127

Bibtex

@article{5a3977007e7a4ecaa421a46acdd304a1,
title = "High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy",
abstract = "Increased levels of karyopherin α2 (KPNA2) expression have been described to be linked to poor prognosis in a variety of malignancies. This study was undertaken to evaluate the clinical impact of KPNA2 expression and its association with key genomic alterations in prostate cancers. A tissue microarray containing samples from 11 152 prostate cancers was analyzed for KPNA2 expression by immunohistochemistry. Results were compared with oncological follow-up data and genomic alterations such as TMPRSS2-ERG fusions and deletions of PTEN, 5q21, 6q15 or 3p13. KPNA2 expression was absent or weak in benign prostatic glands and was found to be in weak, moderate or strong intensities in 68.4% of 7964 interpretable prostate cancers. KPNA2 positivity was significantly linked to the presence of ERG rearrangement (P<0.0001). In ERG-negative and -positive prostate cancers, KPNA2 immunostaining was significantly associated with advanced pathological tumor stage (pT3b/pT4), high Gleason grade and early biochemical recurrence (P<0.0001 each). Multivariate analysis including all established prognostic criteria available after surgery revealed that the prognostic role of KPNA2 (P=0.001) was independent of high Gleason grade, advanced pathological tumor stage, high preoperative prostate-specific antigen level and positive surgical margin status (P<0.0001 each). The comparison of KPNA2 expression with deletions of PTEN, 5q21, 6q15 and 3p13 in ERG-positive and -negative cancers revealed a strong link to PTEN deletions in both subgroups (P<0.0001). In conclusion, the strong independent prognostic impact of KPNA2 expression raises the possibility that measurement of KPNA2 expression alone or in combination with other molecular parameters might possibly result in clinically useful information. The data also emphasize a critical role of the functionality of the nuclear import machinery for prostate cancer biology.",
author = "Katharina Grupp and Mareike Habermann and H{\"u}seyin Sirma and Ronald Simon and Stefan Steurer and Claudia Hube-Magg and Kristina Prien and Lia Burkhardt and Karolina Jedrzejewska and Georg Salomon and Hans Heinzer and Waldemar Wilczak and Martina Kluth and Izbicki, {Jakob R} and Guido Sauter and Sarah Minner and Thorsten Schlomm and Tsourlakis, {Maria Christina}",
year = "2014",
month = jan,
day = "1",
doi = "10.1038/modpathol.2013.127",
language = "English",
volume = "27",
pages = "96--106",
journal = "MODERN PATHOL",
issn = "0893-3952",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy

AU - Grupp, Katharina

AU - Habermann, Mareike

AU - Sirma, Hüseyin

AU - Simon, Ronald

AU - Steurer, Stefan

AU - Hube-Magg, Claudia

AU - Prien, Kristina

AU - Burkhardt, Lia

AU - Jedrzejewska, Karolina

AU - Salomon, Georg

AU - Heinzer, Hans

AU - Wilczak, Waldemar

AU - Kluth, Martina

AU - Izbicki, Jakob R

AU - Sauter, Guido

AU - Minner, Sarah

AU - Schlomm, Thorsten

AU - Tsourlakis, Maria Christina

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Increased levels of karyopherin α2 (KPNA2) expression have been described to be linked to poor prognosis in a variety of malignancies. This study was undertaken to evaluate the clinical impact of KPNA2 expression and its association with key genomic alterations in prostate cancers. A tissue microarray containing samples from 11 152 prostate cancers was analyzed for KPNA2 expression by immunohistochemistry. Results were compared with oncological follow-up data and genomic alterations such as TMPRSS2-ERG fusions and deletions of PTEN, 5q21, 6q15 or 3p13. KPNA2 expression was absent or weak in benign prostatic glands and was found to be in weak, moderate or strong intensities in 68.4% of 7964 interpretable prostate cancers. KPNA2 positivity was significantly linked to the presence of ERG rearrangement (P<0.0001). In ERG-negative and -positive prostate cancers, KPNA2 immunostaining was significantly associated with advanced pathological tumor stage (pT3b/pT4), high Gleason grade and early biochemical recurrence (P<0.0001 each). Multivariate analysis including all established prognostic criteria available after surgery revealed that the prognostic role of KPNA2 (P=0.001) was independent of high Gleason grade, advanced pathological tumor stage, high preoperative prostate-specific antigen level and positive surgical margin status (P<0.0001 each). The comparison of KPNA2 expression with deletions of PTEN, 5q21, 6q15 and 3p13 in ERG-positive and -negative cancers revealed a strong link to PTEN deletions in both subgroups (P<0.0001). In conclusion, the strong independent prognostic impact of KPNA2 expression raises the possibility that measurement of KPNA2 expression alone or in combination with other molecular parameters might possibly result in clinically useful information. The data also emphasize a critical role of the functionality of the nuclear import machinery for prostate cancer biology.

AB - Increased levels of karyopherin α2 (KPNA2) expression have been described to be linked to poor prognosis in a variety of malignancies. This study was undertaken to evaluate the clinical impact of KPNA2 expression and its association with key genomic alterations in prostate cancers. A tissue microarray containing samples from 11 152 prostate cancers was analyzed for KPNA2 expression by immunohistochemistry. Results were compared with oncological follow-up data and genomic alterations such as TMPRSS2-ERG fusions and deletions of PTEN, 5q21, 6q15 or 3p13. KPNA2 expression was absent or weak in benign prostatic glands and was found to be in weak, moderate or strong intensities in 68.4% of 7964 interpretable prostate cancers. KPNA2 positivity was significantly linked to the presence of ERG rearrangement (P<0.0001). In ERG-negative and -positive prostate cancers, KPNA2 immunostaining was significantly associated with advanced pathological tumor stage (pT3b/pT4), high Gleason grade and early biochemical recurrence (P<0.0001 each). Multivariate analysis including all established prognostic criteria available after surgery revealed that the prognostic role of KPNA2 (P=0.001) was independent of high Gleason grade, advanced pathological tumor stage, high preoperative prostate-specific antigen level and positive surgical margin status (P<0.0001 each). The comparison of KPNA2 expression with deletions of PTEN, 5q21, 6q15 and 3p13 in ERG-positive and -negative cancers revealed a strong link to PTEN deletions in both subgroups (P<0.0001). In conclusion, the strong independent prognostic impact of KPNA2 expression raises the possibility that measurement of KPNA2 expression alone or in combination with other molecular parameters might possibly result in clinically useful information. The data also emphasize a critical role of the functionality of the nuclear import machinery for prostate cancer biology.

U2 - 10.1038/modpathol.2013.127

DO - 10.1038/modpathol.2013.127

M3 - SCORING: Journal article

C2 - 23887301

VL - 27

SP - 96

EP - 106

JO - MODERN PATHOL

JF - MODERN PATHOL

SN - 0893-3952

IS - 1

ER -